安徽丰原药业股份有限公司 关于控股股东及其一致行动人协议转让 公司部分股份过户完成的公告 本公司控股股东及其一致行动人和受让方保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 安徽丰原药业股份有限公司（以下简称"公司"或"上市公司"）于 2025 年 9 月 3 日收到控股股东安徽丰原集团有限公司（以下简称"丰原集团"）及其一致行动人马 鞍山丰原企业管理有限公司（简称"马鞍山丰原"）的通知，丰原集团和马鞍山丰原 向海南贵和达毅投资合伙企业（有限合伙）（以下简称"贵和达毅"）协议转让公司部 分股份事项已在中国证券登记结算有限责任公司办理完成过户登记手续，并取得《证 券过户登记确认书》，现将具体情况公告如下： 一、本次协议转让的基本情况 2025 年 8 月 11 日丰原集团和马鞍山丰原与贵和达毅签订了《股份转让协议》， 协议约定：丰原集团、马鞍山丰原合计将其持有的上市公司股份 23,698,554 股（占 公司总股本的 5.1%）转让给贵和达毅，转让价格为 6.72 元/股，股份转让 ...

2024 年度利润分红款的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司持有徽商银行股份有限公司（以下简称"徽商银行"）股份 40,367,250 股。根据徽商银行 2024 年度股东大会审议通过的 2024 年度利润分 配方案（每 10 股派送现金股息人民币 2.1 元（含税）），本公司已于近日收到徽 商银行派送的现金股息人民币 8,477,122.50 元，所得现金红利将增加本公司 2025 年度投资收益。 证券代码：000153 证券简称：丰原药业 公告编号：2025-027 关于收到徽商银行股份有限公司 安徽丰原药业股份有限公司 董 事 会 二〇二五年八月二十六日 特此公告。 ...

Core Viewpoint - Fengyuan Pharmaceutical (000153) reported a significant decline in net profit and revenue for the first half of 2025, indicating challenges in its financial performance [1] Financial Performance Summary - The company's total revenue for the reporting period was 2.027 billion yuan, a year-on-year decrease of 12.16% [1] - Net profit attributable to shareholders was 76.2785 million yuan, down 23.88% year-on-year [1] - In Q2, total revenue was 1.086 billion yuan, a decline of 8.49% year-on-year, with net profit of 38.2577 million yuan, down 28.09% [1] - Gross margin was 19.75%, a decrease of 15.43% year-on-year, while net margin was 3.7%, down 13.55% [1] - Total selling, administrative, and financial expenses amounted to 274 million yuan, accounting for 13.54% of revenue, a decrease of 16.87% year-on-year [1] - Earnings per share were 0.16 yuan, down 23.89% year-on-year [1] Changes in Financial Items - Sales expenses decreased by 34.73% due to reduced market expansion costs [2] - Income tax expenses decreased by 63.47% due to a reduction in total profit compared to the previous year [3] - Net cash flow from financing activities increased by 186.56% due to higher cash received from borrowings [3] - Other income decreased by 48.70% due to a reduction in government subsidies related to daily operations [3] - Investment income dropped by 100.01% as no investment dividends were received [3] - Impairment losses on assets increased by 122.46% due to higher provisions for inventory write-downs [3] - Non-operating expenses surged by 2091.92% due to increased donation expenditures [3] Business Evaluation - The company's return on invested capital (ROIC) was 6.59%, indicating average capital returns [4] - The net profit margin was 3.68%, suggesting low added value for products or services after accounting for all costs [4] - Historical data shows a median ROIC of 5.47% over the past decade, indicating weak investment returns [4] Business Model - The company's performance is primarily driven by marketing efforts, necessitating a thorough examination of the underlying factors behind this drive [5] Financial Health Indicators - The cash flow situation is concerning, with cash and cash equivalents to current liabilities at only 10.73% and a three-year average operating cash flow to current liabilities at 15.59% [6] - The debt situation is also a concern, with interest-bearing debt ratio reaching 20.66% [6] - Accounts receivable have reached 674.62% of profit, indicating potential issues with receivables management [6]

Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) released its semi-annual report for 2025, indicating a total institutional holding of 141 million shares, accounting for 30.39% of the company's total equity, with a slight decrease of 0.36 percentage points from the previous quarter [1] Institutional Holdings - As of August 21, 2025, seven institutional investors disclosed their holdings in Fengyuan Pharmaceutical, with a combined shareholding of 141 million shares [1] - The institutional investors include Anhui Wuwei Pharmaceutical Factory, Bengbu Tushan Enterprise Management Co., Ltd., Ma'anshan Fengyuan Enterprise Management Co., Ltd., Anhui Fengyuan Group Co., Ltd., Great Wall Guorong Investment Management Co., Ltd., BARCLAYS BANK PLC, and Guojin 300 Index Enhanced A [1] - The total institutional holding percentage decreased by 0.36 percentage points compared to the previous quarter [1] Public Fund and Foreign Investment - One new public fund disclosed its holdings this period, namely Guojin 300 Index Enhanced A [1] - Two public funds that were previously disclosed did not report this quarter, including Guojin CSI A500 Index Enhanced A and Dongxing Lianzhong One-Year Holding Period Mixed A [1] - One new foreign institution disclosed its holdings, BARCLAYS BANK PLC, while MORGAN STANLEY & CO. INTERNATIONAL PLC was not reported this quarter [1]

Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [3] - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period [5] - There were no preferred shareholders or related holdings reported during the reporting period [5] Group 2 - All directors attended the board meeting to review the report [2] - The report does not require retrospective adjustments or restatements of previous accounting data [4] - There are no significant matters reported during the period [5]

Core Viewpoint - Fengyuan Pharmaceutical reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 2.027 billion yuan, a year-on-year decrease of 12.16% [2] - The net profit attributable to shareholders was around 76.28 million yuan, reflecting a year-on-year decline of 23.88% [2] - Basic earnings per share were reported at 0.1641 yuan, down 23.89% compared to the previous year [2]

Core Insights - Fengyuan Pharmaceutical (000153.SZ) reported a revenue of 2.027 billion yuan for the first half of 2025, representing a year-on-year decline of 12.16% [1] - The net profit attributable to shareholders was 76.2785 million yuan, down 23.88% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 60.5262 million yuan, a decrease of 29.32% compared to the previous year [1] - The basic earnings per share stood at 0.1641 yuan [1]

安徽丰原药业股份有限公司 2025 年半年度财务报告 安徽丰原药业股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 安徽丰原药业股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：安徽丰原药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 188,225,673.83 | 250,820,984.69 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 1,085,026,202.64 | 934,569,467.81 | | 应收款项融资 | 25,041,019.15 | 32,676,575.46 | | 预付款项 | 64,861,353.22 | 83,581,427.14 | | 应收保费 | | ...

安徽丰原药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算的 会计科目 2025 年期初占用 资金余额 2025 年半年度占用累计 发生金额（不含利息） 2025 年半年度占用 资金的利息（如有） 2025 年半年度偿 还累计发生金额 2025 年半年度期 末占用资金余额 占用形成原因 占用性质 控股股东、实际控制 人及其附属企业 非经营性占用 小计 前控股股东、实际控 制人及其附属企业 非经营性占用 小计 其他关联方及其附 属企业 非经营性占用 小计 总计 其他关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算的 会计科目 2025 年期初往来 资金余额 2025 年半年度往来累计 发生金额（不含利息） 2025 年半年度往来 资金的利息（如有） 2025 年半年度偿 还累计发生金额 2025 年半年度期 末往来资金余额 往来形成原因 往来性质（经营性往 来、非经营性往来） 控股股东、实际控制 人及其附属企业 上市公司的子公司 及其附属企业 安徽泰服医药有限公司 ...

Financial Performance - The company's operating revenue for the reporting period was CNY 2,027,143,954.81, a decrease of 12.16% compared to CNY 2,307,876,468.11 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 76,278,476.53, down 23.88% from CNY 100,212,492.64 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 60,526,212.25, a decline of 29.32% compared to CNY 85,638,373.28 in the same period last year[21]. - The net cash flow from operating activities was CNY 28,142,889.92, which is 13.44% lower than CNY 32,511,792.92 in the previous year[21]. - Operating profit was 88.6749 million yuan, down 34.18% year-on-year[28]. - Total profit amounted to 88.4324 million yuan, reflecting a decline of 34.76% from the previous year[28]. - The basic earnings per share decreased to CNY 0.1641, down 23.89% from CNY 0.2156 in the same period last year[21]. - The weighted average return on net assets was 3.71%, down from 5.16% in the previous year, a decrease of 1.45%[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,840,465,039.70, reflecting a 3.01% increase from CNY 4,698,947,415.21 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 3.70% to CNY 2,094,240,186.77 from CNY 2,019,573,061.58 at the end of the previous year[21]. - The company's inventory decreased by 1.10% to ¥557,536,183.56, compared to ¥593,108,354.64 at the end of the previous year[45]. - The accounts receivable increased by 22.42% to ¥1,085,026,202.64, compared to ¥934,569,467.81 at the end of the previous year[45]. - Total liabilities increased to ¥2,721,039,273.97 from ¥2,653,036,981.33, representing a growth of about 2.6%[115]. - Current liabilities totaled ¥2,225,277,676.04, up from ¥2,188,094,915.89, marking an increase of approximately 1.9%[115]. Cash Flow - The company reported a significant increase in net cash flow from financing activities, which rose by 186.56% to ¥68,186,034.34, compared to ¥23,794,892.37 in the previous year[39]. - The net cash flow from operating activities decreased by 13.44% to ¥28,142,889.92, down from ¥32,511,792.92 in the previous year[39]. - The net cash flow from investing activities was -¥33,323,198.72, an improvement from -¥55,417,869.60 in the first half of 2024[128]. - Cash inflow from financing activities was ¥514,219,828.53, slightly lower than ¥523,853,270.24 in the previous year[128]. Research and Development - Research and development expenses increased by 21.37% to ¥31,993,776.84, compared to ¥26,360,784.48 in the previous year[39]. - The company focuses on new drug research and development, holding multiple national first and second-class new drug varieties and several proprietary intellectual property products[29]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The total number of common stock shareholders at the end of the reporting period is 34,308[103]. - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.80% of shares, totaling 50,178,992 shares[103]. Corporate Governance and Compliance - The semi-annual financial report has not been audited[78]. - There were no penalties or rectification situations reported during the period[80]. - The company has not reported any major events related to its subsidiaries during the reporting period[97]. - There are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[76]. Market and Operational Risks - The company emphasizes the high risks associated with new drug development, which may impact the recovery of investments and expected benefits if new drug registrations are not approved[6]. - The company is facing risks related to pharmaceutical policy changes, which may impact market competition and future development[60]. - The company has invested in a venture capital fund, which may face long investment recovery periods and risks of underperformance due to market conditions[60]. Environmental and Social Responsibility - The company plans to enhance its environmental protection measures to comply with increasing regulatory requirements and reduce operational risks[61]. - The company has included 7 subsidiaries in the list of enterprises required to disclose environmental information legally[72]. Financial Reporting and Accounting Policies - The company adheres to the accounting standards and principles set forth by the relevant regulations, ensuring accurate financial reporting[151]. - The company uses RMB as its functional currency for financial reporting[154]. - The company has established specific thresholds for recognizing significant bad debt provisions and other financial activities, with amounts exceeding RMB 500,000 for receivables and RMB 5 million for investment activities being considered significant[155].